Sign in Subscribe

FDA Panel Backs Replimune’s Melanoma Drug After Multiple Rejections

FDA panel votes 10-3 for Replimune’s RP1 melanoma drug after two rejections, citing benefits for resistant patients despite messy data.

FDA Panel Backs Replimune’s Melanoma Drug After Multiple Rejections
Credit: Replimune
Already have an account? Sign in.